Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
de Boer, NK; Reinisch, W; Teml, A; van Bodegraven, AA; Schwab, M; Lukas, M; Ochsenkühn, T; Petritsch, W; Knoflach, P; Almer, S; van der Merwe, SW; Herrlinger, KR; Seiderer, J; Vogelsang, H; Mulder, CJ; Dutch 6-TG working group.
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
DIGESTION. 2006; 73(1): 25-31.
Doi: 10.1159/000091662
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Petritsch Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6-12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use
- Congresses as Topic -
- Drug-Induced Liver Injury -
- Drug-Induced Liver Injury -
- Humans -
- Inflammatory Bowel Diseases - drug therapy
- Thioguanine - adverse effects Thioguanine - therapeutic use
- Find related publications in this database (Keywords)
- 6-thioguanine
- thiopurine
- inflammatory bowel disease
- Crohn's disease and ulcerative colitis